About Us

We work closely with our clients to manufacture products destined for patients all over the world. C3i prides itself on delivering, on time, quality results on behalf of its clients and for patients, advanced cell and gene products that meet regulatory requirements around the world.

Our Vision

Our vision is to make life-saving cell & gene therapies available to everyone who needs it. Our team truly understands that we are not just working with the patient’s cells but with a loved one’s chance at life.

“Our constant effort in manufacturing and testing is rewarded by giving the patient another opportunity in life.”

Our Mission

C3i’s mission is to develop and manufacture cost-effective state-of-the-art integrated cell and gene therapies making it accessible to people in need.

Our Values

We work in partnership with our clients to ensure we put patients first and are driven to perform our best knowing that the cells in our hands impact the patient’s survival.

“C3i works as part of your team proudly blurring the lines between you and us to the most desirable we


Our values define who we are and how we pursue our mission and vision.

  • Excellence
  • Responsiveness
  • Collaboration
  • Empathy
  • Integrity
Our People

Meet our successful team

We are a team of rigorous and solution-driven scientists with a long history of cell therapy development and manufacturing experience.
  • Board of Directors

    • Louis Lacasse Chairman of the board and President of GeneChem
    • Timothy Smith CEO and Co-Founder of Octane Inc
    • Isabelle Riviere Vice-President, Head of Oncology Cell Therapy Technologies and Product Engine at Takeda
    • Thomas Tradler Head of Business Development and Patent Management at Fraunhofer IZI
    • Lambert Busque Chief Medical Officer, Hematolo-oncologists & Chief of Molecular Diagnostics at Maisonneuve-Rosemont Hospital
    • Denis-Claude Roy Chief Scientific Officer, Director Hematology-Oncology & Cell Therapy University Institute at Maisonneuve-Rosemont Hospital
    • Janet Dancey Director, National Cancer Institute of Canada (NCIC) Clinical Trials Group
    • William Brock Partner at Davies Ward Phillips and Vineberg
    • Bernard Massie Director General, Human Health Therapeutics, National Research Council of Canada (Retired)
    • Kathryn Hayashi CEO at TRIUMF Innovations Inc
    • Chantale Lauzon Director, Taxation for Domtar Group
  • Management Team

    • Louisa Petropoulos Chief Executive Officer
    • Denis-Claude Roy Chief Scientific Officer
    • Lambert Busque Chief Medical Officer
    • Olivier Mailloux Chief Financial Officer
    • Eleonora Forero Vice-President of Operations
    • Sandra (Sam) Donaldson Vice-President, Business Development
Our Partners

We work with the best